Abstract: 2-Amino-N-(1,2-diphenyl-1-methylethyl) acetamide (remacemide), or a pharmaceutically acceptable salt thereof, for use in the treatment of Parkinson's disease is disclosed.

Abstract: New compounds of the formula (A) ##STR1## a process for their preparation and their use in the manufacture of pharmaceutical preparations. The new compounds have both local anaesthetic and analgesic effect.

Abstract: Compounds of the formula I as well as methods for their preparation, their pharmaceutical preparations and their use. ##STR1## The compounds of formula I are useful in therapy, especially as analgesics and as immunosuppresive agents.

Abstract: The invention concerns the compounds of the formulas: ##STR1## and protected forms and salts thereof which serve as starting materials in an improved method of synthesizing thrombin and kininogenase inhibitors. The invention further concerns an improved method for synthesizing the inhibitors which utilizes the compounds.

Abstract: Compounds of formula (I) ##STR1## in which R.sub.1 is hydrogen, R.sub.2 is hydrogen or C.sub.1-6 alkyl, R.sub.3 and R.sub.4 independently represent one or more radicals selected from hydrogen, NH.sub.2, NO.sub.2, halogen, hydroxy, C.sub.1-6 alkoxy or C.sub.1-6 alkyl, X represents S or --CH.dbd.CH-- group and pharmaceutically acceptable salts are NMDA receptor antagonists.

Abstract: Compounds of the formula I, ##STR1## are NMDA antagonists and useful in the treatment and prevention of nervous system related pathological conditions resulting from overstimulation by excitatory amino acids. Methods for their preparation and pharmaceutical compositions containing them are also comprised according to the invention.

Abstract: Use of a pharmaceutically acceptable salt of ropivacaine for the manufacture of a pharmaceutical preparation with sensoric block and minimal motor blockade.

Abstract: A recombinant DNA construct, useful for obtaining excretion from E. coli of a heterologous protein, comprises a coding region in which DNA coding for the heterologous protein in coupled in reading frame with DNA coding for the OmpA signal peptide, to enable secretion of the protein into the periplasm; and a control region linked operably with the coding region to enable expression thereof in an E. coli host, wherein the control region comprises the tac promoter, the lac operator and a consensus ribosome binding site. With this construct, the excretion of heterologous proteins from E. coli can be achieved, consistently and for a wide variety of such proteins, without assistance from carrier proteins or membrane-lytic agent and by using "healthy" hosts rather than mutant strains having defective outer membranes.

Abstract: There is provided a method of treatment of neurological disorders, such as epilepsy, stroke and cerebral ischaemia, which comprises the administration of a compound of Formula I: ##STR1## wherein, Ar.sub.1 and Ar.sub.2, which may be the same or different, independently represent phenyl or phenyl substituted by one or more of amino, nitro, halogen, hydroxy, C1 to 6 alkoxy, C1 to 6 alkyl or cyano;R.sub.1 represents hydrogen, C1 to 6 alkyl, C1 to 6 alkoxycarbonyl;R.sub.2 represents hydrogen or COCH.sub.2 NH.sub.2 ;R.sub.3 represents hydrogen or C1 to 6 alkyl;in addition, when R.sub.2 represents hydrogen either one or both of Ar.sub.1 and Ar.sub.2 may also represent 2-, 3- or 4-pyridinyl and R.sub.1 may also represent trihalomethyl;or a pharmaceutically acceptable salt thereof.Some of the compounds of formula I are novel, and these are also provided, together with pharmaceutical compositions containing the novel compounds.

Abstract: This invention relates to novel dermorphin analogs having pharmacological activity. More particularly, this invention relates to novel tetrapeptides having specific structural features and a net charge of +2 or greater. The peptides of this invention are useful in treating pain and gastro-intestinal disorders. Accordingly, this invention also relates to pharmaceutical compositions comprising those peptides and methods for treating pain and gastro-intestinal disorders.

Abstract: Compounds of general formula I, ##STR1## wherein R.sup.1 represents hydrogen or alkyl C.sub.1-3,R.sup.2 represents hydrogen, alkyl C.sub.1-6, alkenyl C.sub.3-6 or alkynyl C.sub.3-6,n and m are integers from 1 to 3, provided that n+m=4, andone of X and Y represents CH.sub.2 and the other represents CHR.sup.3, C=CHR.sup.4 or C=NR.sup.5, in whichR.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.11, R.sup.12, R.sup.13, R.sup.14, R.sup.15, R.sup.16 and R.sup.17 are as defined in the specification,and their saltsare useful as pharmaceuticals, in particular as central muscarinic acetylcholine receptors. The compounds are therefore useful in the treatment of diseases such as presenile and senile dementia, Huntington's chorea, tardive dyskinesia, hyperkinesia, mania and Tourette Syndrome, and also as analgesic agents for use in the treatment of severe painful conditions such as rheumatism, arthritis, and terminal illness.